Cutaneous squamous cell carcinoma (SCC)
SCC ranges from a local tumour with a high likelihood of cure to a higher-risk disease that requires broader staging and multidisciplinary planning.
Clinical TNM, pathological groups, site distinctions and staging limitations.
How it may appear
A persistent scaly or crusted area, a nodule, a non-healing ulcer, a bleeding lesion or rapid change in a pre-existing skin abnormality. Appearance alone cannot establish the diagnosis.
Why biopsy matters
Histology confirms SCC and reports features that influence risk, including differentiation, depth, perineural invasion and other characteristics. The biopsy method is selected according to size and site.
Higher-risk features
- larger size or deeper invasion;
- ear, lip or another complex anatomical site;
- recurrence, indistinct borders or rapid growth;
- immunosuppression or neurological symptoms;
- adverse pathological features.


Special clinical context: cSCC in epidermolysis bullosa
The author presentation includes a separate case labelled cutaneous squamous cell carcinoma in the setting of epidermolysis bullosa. This is not a typical or universal cSCC scenario, so it is presented as a distinct clinical context rather than a management template for other patients.
cSCC in epidermolysis bullosa. The author series shows an overview of the affected limb and a closer view of the tumour.Author clinical archive. Published with confirmed permission.
The photograph does not establish stage, depth of invasion, regional nodal status or the required operation. Those require pathology, clinical staging and the full case context.
Author clinical spectrum: distal sites
Hand and lower-leg location changes more than appearance. After oncologically adequate excision, the remaining defect may require separate planning for function, tendon or bone coverage and reconstruction.
Reconstruction after skin cancer removal →
Clinical findings and histology belong together



Anatomy that changes management
Imaging in 2026 - when risk can no longer be assessed by inspection alone
A multidisciplinary Delphi consensus recommends staging and surveillance imaging for localized cSCC with an estimated metastatic risk of about 15% or higher. Scenarios supporting imaging included concern for metastasis, bone invasion, extension beyond subcutaneous fat, large-calibre nerve invasion, diameter at least 4 cm, and selected combinations of poor differentiation, LVI, deep invasion and PNI.
CT was the preferred modality for nodal staging and surveillance in the consensus. In selected patients, imaging surveillance was recommended for at least 2 years, with near-consensus for 3 years. This does not mean routine CT for every patient with cSCC.
cSCC 2026: higher-risk and difficult-to-treat
The 2026 EADO update refines risk stratification and introduces a dedicated difficult-to-treat cSCC framework for situations where standard local treatment is inadequate or unacceptably morbid.
Primary / easy-to-treat
Most local primary cSCC with a predictable surgical pathway.
Higher-risk
Risk is driven by depth, size, PNI, site, host factors, recurrence and pathology.
DTT-cSCC
Requires broader MDT assessment of surgery, radiotherapy, systemic treatment, imaging and functional cost.
When nodal imaging matters
New 2026 consensus guidance supports staging/surveillance imaging in patients with substantial metastatic risk, approximately 15% or higher, with modality individualized to anatomy and risk.
AJCC 8 for cutaneous carcinoma of the head and neck
This AJCC 8 system applies to cutaneous squamous cell and basal cell carcinoma of the head and neck; it is not a universal staging system for every skin site. Eyelid carcinoma has a separate AJCC 8 chapter and TNM system.
| Stage | TNM / grade | What it means |
|---|---|---|
| Tis | Tis | Carcinoma in situ. |
| T1 | T1 | Tumour ≤2 cm. |
| T2 | T2 | Tumour >2-4 cm. |
| T3 | T3 | Tumour >4 cm, or minor bone erosion, deep invasion or defined perineural invasion. |
| T4a / T4b | T4a / T4b | T4a is gross cortical bone or marrow invasion; T4b is skull-base or skull-base foramen invasion. |
| N0 / N1 | N0 / N1 | N0: no regional nodal metastasis. N1: one ipsilateral node ≤3 cm without extranodal extension. |
| N2 / N3 | N2 / N3 | N2 covers specified single or multiple nodes up to 6 cm; N3 is a node >6 cm or clinically/pathologically significant extranodal extension. |
| M0 / M1 | M0 / M1 | M0: no distant metastasis; M1: distant metastasis. |
| 0 | Tis N0 M0 | Carcinoma in situ. |
| I | T1 N0 M0 | Tumour ≤2 cm without nodal or distant metastases. |
| II | T2 N0 M0 | Tumour >2-4 cm without nodal or distant metastases. |
| III | T1-T2 N1 M0; or T3 N0-N1 M0 | T3 without advanced nodal disease, or a smaller tumour with one small ipsilateral node and no extranodal extension. |
| IV | T1-T3 N2 M0; or T4 any N M0; or any T N3 M0; or any T/N M1 | More extensive nodal disease, bone/skull-base invasion or distant metastasis. |
Sources: AJCC Current Staging System 2026 - Cutaneous Carcinoma of the Head and Neck and Eyelid Carcinoma, 8th edition; NCI Skin Cancer Treatment PDQ.
Treatment
Surgical removal with margin control is the main treatment for most operable SCCs. High-risk disease may require regional node assessment, imaging, radiotherapy or systemic treatment within a multidisciplinary plan.
Adjuvant cemiplimab after surgery + radiotherapy
This applies to selected high-risk patients after definitive surgery and postoperative radiotherapy. It does not mean that routine cSCC requires immunotherapy. Overall-survival benefit was not established in the primary publication.
Safety in C-POST: grade 3 or higher adverse events occurred in 23.9% with cemiplimab versus 14.2% with placebo; treatment discontinuation due to adverse events occurred in 9.8% versus 1.5%. The absolute benefit therefore needs to be weighed against recurrence risk, comorbidity and patient priorities.
Reconstruction
On the face, ear and other functional sites, closure is planned alongside excision but without compromising tumour control.
Clinical images from the author's archive, published with confirmed consent. They are not intended for self-diagnosis.
This educational material does not replace clinical examination, a complete pathology report or an individual treatment plan.


